Acknowledgments
We would like to thank all EGFR testing participating laboratories (in alphabetical order): ACTC (http://en.actc-lab.chem.uoa.gr/), contact: E. S. Lianidou; Bioiatriki (bioiatriki.gr), contact: Dr. E. Tsitsopoulos; Biopath Innovations SA (http://www.biopathinnovations.com/), contact: Dr. S. Murray; First Department of Pathology, National and Kapodistrian University of Athens, Medical School, Athens, Greece: Dr. A. Saetta, Assoc. Professor; Genekor (www.genekor.com), contact: Dr. G. Nasioulas; Genotypos (www.genotypos.gr), contact: Dr. D. Christou; IASO General Hospital, Pathology Laboratory, contact: E. Patsea; Karyo (http://www.karyo.gr/), contact: T. Papadopoulos. We would also like to thank Astra Zeneca, Greece and especially Dr. Fotini Papageorgiou, for providing the reference standards used in this study.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: Astra Zeneca, Greece.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Lianidou E, Hoon D. Circulating tumor cells and circulating tumor DNA. In: Rifai N, Horvath AR, Wittwer C, editors. Tietz textbook of clinical chemistry and molecular diagnostics, 6th ed. St Louis, Missouri: Elsevier, 2017:1111–44.Search in Google Scholar
2. Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 2016;6:479–91.10.1158/2159-8290.CD-15-1483Search in Google Scholar PubMed
3. International Organization for Standardization. ISO15189 Medical Laboratories – requirements for quality and competence, 3rd ed. 2012. http://www.tecmoh.com/mypages/guides/CwgXKF9s1c.pdfSearch in Google Scholar
4. International Organization for Standardization. ISO17043 Conformity assessment – general requirements for proficiency testing, 1st ed. 2010. https://webstore.iec.ch/preview/info_isoiec17043%7Bed1.0%7Den.pdfSearch in Google Scholar
5. Karlovich C, Goldman JW, Sun JM, Mann E, Sequist LV, Konopa K, et al. Assessment of EGFR variant status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686). Clin Cancer Res 2016;22:2386–95.10.1158/1078-0432.CCR-15-1260Search in Google Scholar PubMed PubMed Central
6. Karachaliou N, Mayo-De Las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, et al. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial. JAMA Oncol 2015;1:149–57.10.1001/jamaoncol.2014.257Search in Google Scholar PubMed
7. Marchetti A, Palma JF, Felicioni L, De Pas TM, Chiari R, Del Grammastro M, et al. Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients. J Thorac Oncol 2015;10:1437–43.10.1097/JTO.0000000000000643Search in Google Scholar PubMed
8. Oxnard GR, Paweletz CP, Kuang Y, De Pas TM, Chiari R, Del Grammastro M, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014;20:1698–705.10.1158/1078-0432.CCR-13-2482Search in Google Scholar PubMed PubMed Central
9. Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol 2016;34:3375–82.10.1200/JCO.2016.66.7162Search in Google Scholar PubMed PubMed Central
10. van Krieken JH, Siebers AG, Normanno N. European consensus conference for external quality assessment in molecular pathology. Ann Oncol 2013;24:1958–63.10.1093/annonc/mdt153Search in Google Scholar PubMed
11. Patton S, Normanno N, Blackhall F, Murray S, Kerr KM, Dietel M, et al. Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. Br J Cancer 2014;111:413–20.10.1038/bjc.2014.353Search in Google Scholar PubMed PubMed Central
12. Keppens C, Palma JF, Das PM, Scudder S, Wen W, Normanno N, et al. Detection of EGFR variants in plasma: a multilaboratory comparison of a real-time PCR EGFR Mutation Test in Europe. J Mol Diagn 2018;20:483–94.10.1016/j.jmoldx.2018.03.006Search in Google Scholar PubMed
13. Fassunke J, Ihle MA, Lenze D, Lehmann A, Hummel M, Vollbrecht C, et al. EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial. Virchows Arch 2017;471:509–20.10.1007/s00428-017-2226-8Search in Google Scholar PubMed
©2019 Walter de Gruyter GmbH, Berlin/Boston
